Tamoxifen reduces plasma homocysteine levels in healthy women (Q36292930)

13 August 2017

Tamoxifen reduces plasma homocysteine levels in healthy women (English)

1 reference

13 August 2017

1 reference

Cattaneo M

1

1 reference

13 August 2017

Baglietto L

2

1 reference

13 August 2017

Zighetti ML

3

1 reference

13 August 2017

Bettega D

4

1 reference

13 August 2017

Robertson C

5

1 reference

13 August 2017

Costa A

6

1 reference

13 August 2017

Mannucci PM

7

1 reference

13 August 2017

Decensi A

8

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

British Journal of Cancer

13 August 2017

1 reference

13 August 2017

77

1 reference

13 August 2017

12

1 reference

13 August 2017

2264-2266

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.1998.376

13 August 2017

0 references

cites work

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Nonadrenergic inhibitory innervation to the airways of the newborn cat.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Breast Cancer Prevention Trial takes off

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Effect of tamoxifen on measurements of hemostasis in healthy women

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Hyperhomocysteinemia as a risk factor for deep-vein thrombosis.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2150392

Plasma homocysteine levels and mortality in patients with coronary artery disease

22 September 2018

1 reference

12 December 2020

The case for clinical trials of tamoxifen for prevention of breast cancer

1 reference

12 December 2020

Risk of endometrial cancer after tamoxifen treatment of breast cancer

1 reference

12 December 2020

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

12 December 2020

Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen

1 reference

12 December 2020

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

12 December 2020

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

12 December 2020

Drug's link to genes reveals estrogen's many sides

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1998.376

1 reference

13 August 2017

1 reference

13 August 2017

1 reference